Endo International plc (0Y5F.L) LSE
0.00
-0.0006(-50.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Endo International plc
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
2931
First IPO Date
January 26, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Blaise A. Coleman | President, Chief Executive Officer & Director | 12.85M | 1974 |
| Matthew Joseph Maletta | Executive Vice President, Chief Legal Officer & Company Secretary | 4.25M | 1972 |
| James Tursi | Executive Vice President of Global Research & Development | 5.46M | 1965 |
| Patrick A. Barry | Executive Vice President & President of Global Commercial Operations | 6.15M | 1968 |
| Mark T. Bradley | Executive Vice President & Chief Financial Officer | 6.27M | 1969 |
| Cheryl Stouch | Senior Vice President of Information Technology & Chief Information Officer | 0 | N/A |
| Laure E. Park | Senior Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
| Susan Williamson | Senior Vice President & Chief Compliance Officer | 0 | N/A |
| Tracy Basso | Chief Human Resources Officer | 0 | N/A |
| Frank Raciti | Vice President, Controller & Chief Accounting Officer | 0 | N/A |
Description
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
